1
|
Agrawal V, Mishra A, Yadav S, Sharma D, Acharya H, Mishra A, Agrawal R, Chanchlani R. A 10-year study of the outcome of wilms' tumor in central India and identifying practice gaps. J Indian Assoc Pediatr Surg 2022; 27:42-52. [PMID: 35261513 PMCID: PMC8853598 DOI: 10.4103/jiaps.jiaps_314_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 11/26/2020] [Accepted: 06/29/2021] [Indexed: 11/25/2022] Open
Abstract
Introduction: Despite remarkable improvement in Wilms' tumor (WT) survival in Western world, sub-optimal outcome in resource-constrained settings is influenced by late presentation, larger size, and poor access to treatment. This prompted us to study the outcome at a tertiary care center and to identify the global and local practice gaps. Materials and Methods: A retrospective, observational study of WT was conducted from October 2009 to September 2019 at a tertiary care setting. Following the National Wilms' Tumor Study Group protocol, an upfront nephrectomy (unilateral resectable tumors) and preoperative chemotherapy (large/unresectable Stage I–III) were followed. The records were reviewed for demographics, stage, preoperative chemotherapy, predictive factors, and outcome. Survival curves were plotted by the Kaplan–Meier method, and analysis was performed using the SPSS software version 16. Results: One hundred and fifty-six children were included, median age was 4.1 years, with a male predominance. The most common stages of the presentation were II (40.4%) and III (34.6%). An upfront surgery was done in 27.6%, while remaining received preoperative chemotherapy. The median follow-up was 22 months, and the events included relapse in 46 (29.48%) and death in 54 (34.61%). The mean survival time was 45.7 (95% confidence interval [CI], 41.08–50.30). The 2-year overall survival was 65.38% (95% CI, 59–73), and the 2-year event-free survival was 36% (95% CI, 32–41). On comparison of the impact of preoperative chemotherapy, the survival estimates in Stages I–III and relapse rate were statistically similar, tumor size reduced significantly, and tumor spill was significantly lower (P < 0.05). Conclusion: WT is associated with late presentation, sub-optimal survival, and higher relapse in our setting associated with practice gaps related to the management including practice violations.
Collapse
|
2
|
Dome JS, Mullen EA, Dix DB, Gratias EJ, Ehrlich PF, Daw NC, Geller JI, Chintagumpala M, Khanna G, Kalapurakal JA, Renfro LA, Perlman EJ, Grundy PE, Fernandez CV. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. J Natl Compr Canc Netw 2021; 19:978-985. [PMID: 34416705 DOI: 10.6004/jnccn.2021.7070] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 06/09/2021] [Indexed: 11/17/2022]
Abstract
Refinements in surgery, radiation therapy, and chemotherapy since the mid-20th century have resulted in a survival rate exceeding 90% for patients with Wilms tumor (WT). Although this figure is remarkable, a significant proportion of patients continue to have event-free survival (EFS) estimates of <75%, and nearly 25% of survivors experience severe chronic medical conditions. The first-generation Children's Oncology Group (COG) renal tumor trials (AREN '0'), which opened to enrollment in 2006, focused on augmenting treatment regimens for WT subgroups with predicted EFS <75% to 80%, including those with the adverse prognostic marker of combined loss of heterozygosity (LOH) at chromosomes 1p/16q, pulmonary metastasis with incomplete lung nodule response after 6 weeks of chemotherapy, bilateral disease, and anaplastic histology. Conversely, therapy was reduced for patient subgroups with good outcomes and potential for long-term toxicity, such as those with lung metastasis with complete lung nodule response after 6 weeks of chemotherapy. This article summarizes the key findings of the first-generation COG renal tumor studies and their implications for clinical practice.
Collapse
Affiliation(s)
- Jeffrey S Dome
- Division of Oncology, Center for Cancer and Blood Disorders, Children's National Hospital and the Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC
| | - Elizabeth A Mullen
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
| | - David B Dix
- Pediatric Hematology/Oncology, British Columbia Children's Hospital, Vancouver, British Columbia, Canada
| | | | - Peter F Ehrlich
- Department of Pediatric Surgery, University of Michigan, CS Mott Children's Hospital, Ann Arbor, Michigan
| | - Najat C Daw
- Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - James I Geller
- Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | | | - Geetika Khanna
- Department of Radiology, Children's Healthcare of Atlanta, Atlanta, Georgia
| | - John A Kalapurakal
- Department of Radiation Oncology, Northwestern University School of Medicine, Chicago, Illinois
| | - Lindsay A Renfro
- Children's Oncology Group and Division of Biostatistics, University of Southern California, Los Angeles, California
| | - Elizabeth J Perlman
- Department of Pathology, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Cancer Center, Chicago, Illinois
| | - Paul E Grundy
- Department of Pediatrics, University of Alberta Hospital, Edmonton, Alberta, Canada; and
| | - Conrad V Fernandez
- Division of Pediatric Hematology/Oncology, IWK Health Centre, Halifax, Nova Scotia, Canada
| |
Collapse
|
3
|
Long-term Outcome in Children with Wilms’ Tumor; Experience of a Single Center for Two Decades. INTERNATIONAL JOURNAL OF CANCER MANAGEMENT 2021. [DOI: 10.5812/ijcm.102113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: Wilms’ tumor (nephroblastoma) is the major renal cancer in children. Objectives: The aim of this study was to assess the individuality of Wilms’ tumor and the consequences of management attained in our referral subspecialty center. Methods: In this study, we composed the data of children with Wilms’ tumor in 2 decades; 55 cases between 1992 and 2002 and 49 patients between 2006 and 2016 were diagnosed with Wilms’ tumor. Demographic characters, a form of presentation, tumor stage, related underlying disease, histopathology consequences, type of management, and the survival rates were assessed. Results: In the first decade, 24 patients were females and 31 were males (M/F = 1.2); in the other groups, 30 were females and 19 were males (M/F = 0.61). The mean age was 45.2 months at the time of diagnosis for the first group and the mean age was 36 months for the other group. In the first decade, the surgical stage after the operation was as follows: stage I (32.7%), stage II (16.36%), stage III (38.1%), stage IV (9%), and stage V (1.8%) who did not operate. In second decade, 49 patients were as follows: stage I (14.3%), stage II (40.8%), stage III (24.5%), stage IV (10.2%), and stage V (10.2%). In 54.5% of the first group, histology was favorable, and in 43.6% of the first group, histology was unfavorable; in the second group, 95.4% were the favorable type. The patients were managed based on protocols of the National Wilms’ Tumor Study. In the first decade, relapse-free was 71% and 4-year survival rates were estimated at 86%, and in the second decade, pulmonary metastasis was observed at 28.6%, liver metastasis in 2.3%, recurrence in 5%, and 4-year survival rates were estimated at 90%. Conclusions: This study demonstrated development in the management of children with Wilms’ tumor in recent 20 years, with comparable relapse-free and survival rates to the National Wilms’ Tumor study. But with more adjustment in treatment protocols, the superior outcome will be attainable.
Collapse
|
4
|
Richards MK, Goldin AB, Ehrlich PF, Beierle EA, Doski JJ, Goldfarb M, Langer M, Nuchtern JG, Vasudevan S, Gow KW. Partial Nephrectomy for Nephroblastoma: A National Cancer Data Base Review. Am Surg 2018. [DOI: 10.1177/000313481808400315] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Standard of care for unilateral nephroblastoma includes total nephrectomy (TN) with nodal sampling. We sought to compare the outcomes of TN and partial nephrectomy (PN). We performed a retrospective cohort study of TN and PN for nephroblastoma using the National Cancer Data Base. The outcomes included nodal sampling frequency, margin status, and survival. Categorical and continuous data were evaluated with χ2 and t tests, respectively ( P < 0.05). Generalized linear models evaluated nodal sampling and margin status. Cox regression compared survival. In total, 235 patients underwent PN and 3572 had TN. TN patients were 50 per cent more likely to undergo nodal sampling (RR: 1.47, 95% CI 1.30–1.66). There was no difference in margin status (RR: 0.91, 95% CI 0.65–1.28) or overall survival (HR 1.57; 95% CI 0.78–3.19). This study reports the largest review of patients with PN for unilateral nephroblastoma. PN patients had less nodal sampling but similar margin involvement and overall survival.
Collapse
Affiliation(s)
- Morgan K. Richards
- Department of Surgery, University of Washington, Seattle, Washington
- Department of General and Thoracic Surgery, Seattle Children's Hospital, Seattle, Washingon
| | - Adam B. Goldin
- Department of General and Thoracic Surgery, Seattle Children's Hospital, Seattle, Washingon
| | | | | | - John J. Doski
- Methodist Children's Hospital of South Texas, San Antonio, Texas
| | | | | | | | | | - Kenneth W. Gow
- Department of General and Thoracic Surgery, Seattle Children's Hospital, Seattle, Washingon
| |
Collapse
|
5
|
Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg 2017; 265:835-840. [PMID: 27811504 DOI: 10.1097/sla.0000000000001716] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To determine if observation alone after nephrectomy in very low-risk Wilms tumor (defined as stage I favorable histology Wilms tumors with nephrectomy weight <550g and age at diagnosis <2 years) results in satisfactory event-free survival and overall survival, and to correlate relapse with biomarkers. PATIENTS AND METHODS The AREN0532 study enrolled patients with very low-risk Wilms tumor confirmed by central review of pathology, diagnostic imaging, and surgical reports. After nephrectomy, patients were followed without adjuvant chemotherapy. Evaluable tumors were analyzed for WT1mutation, 1p and 16q copy loss, 1q copy gain, and 11p15 imprinting. The study was powered to detect a reduction in 4-year EFS from 87% to 75% and overall survival from 95% to 88%. RESULTS A total of 116 eligible patients enrolled with a median follow up of 80 months (range: 5-97 months). Twelve patients relapsed. Estimated 4-year event-free survival was 89.7% (95% confidence interval 84.1-95.2%) and overall survival was 100%. First sites of relapse were lung (n = 5), tumor bed (n = 4), and abdomen (n = 2), with one metachronous tumor in the contralateral kidney (n = 1) at a median time of 4.3 months for those who relapsed (range 2.3-44 months). The presence of intralobar (P = 0.46) or perilobar rests (P = 1.0) were not associated with relapse (P = 0.16). 1q gain, 1p and 16q loss, and WT1 mutation status were not associated with relapse. 11p15 methylation status was associated relapse (20% relapse with loss of heterozygosity, 25% with loss of imprinting, and 3.3% relapse with retention of the normal imprinting (P = 0.011)). CONCLUSIONS Most patients meeting very low-risk criteria can be safely managed by nephrectomy alone with resultant reduced exposure to chemotherapy. Expansion of an observation alone strategy for low-risk Wilms tumor incorporating both clinical features and biomarkers should be considered.
Collapse
|
6
|
Ferrer FA, Herbst KW, Fernandez CV, Khanna G, Dome JS, Naranjo A, Mullen EA, Geller JI, Gratias EJ, Shamberger R, Ritchey M, Ehrlich PF. Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placement. J Pediatr Urol 2014; 10:969-73. [PMID: 24863984 PMCID: PMC4339089 DOI: 10.1016/j.jpurol.2014.02.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Accepted: 02/10/2014] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Patients with stage I Wilms tumor, age ≤ 2 years, tumor ≤ 550 g may not require therapy beyond nephrectomy. This study's aims were to determine: (1) if a linear relationship exists between tumor weight and computed tomography (CT) estimated volume; (2) describe the accuracy of a slope-intercept equation in estimating weight; and (3) determine the potential impact of weight estimation on port placement decisions. MATERIALS AND METHODS Tumor weight and port placement information were abstracted from 105 patients, age ≤ 2 years, with tumors ± 550 g, enrolled in COG AREN03B2. One radiologist estimated tumor size from CT scan. Prolate ellipse volume (PEV) was calculated, linear regression performed, slope-intercept equation calculated, equation estimated weight determined, and potential impact of the on port placement evaluated. RESULTS A strong relationship exists between PEV and weight (R(2) = 0.87). The slope-intercept equation for weight was: weight = 1.04(PEV) + 58.75. Overall median relative error for the equation was 0.9%, and -3% in tumors weighing 350-750 g. Fifty-five ports were placed, 29 in patients with tumor weight ≤ 550 g, and six not placed in patients with tumor weight > 550 g. CONCLUSIONS The relationship between PEV and weight produced a reliable weight prediction equation. Preoperative consideration of specimen weight may diminish the number of ports placed in this population.
Collapse
Affiliation(s)
- Fernando A Ferrer
- Connecticut Children's Medical Center, University of Connecticut Medical School, 282 Washington Street, Hartford, CT 06106, USA.
| | - Katherine W Herbst
- Connecticut Children's Medical Center, University of Connecticut Medical School, 282 Washington Street, Hartford, CT 06106, USA.
| | | | - Geetika Khanna
- Washington University School of Medicine, St. Louis, MO, USA.
| | - Jeffrey S Dome
- Children's National Medical Center, Washington, DC, USA.
| | - Arlene Naranjo
- Children's Oncology Group Statistics & Data Center, University of Florida, Gainesville, FL, USA.
| | | | - James I Geller
- Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
| | | | | | | | | |
Collapse
|
7
|
Pshak TJ, Cho DS, Hayes KL, Vemulakonda VM. Correlation between CT-estimated tumor volume, pathologic tumor volume, and final pathologic specimen weight in children with Wilms' tumor. J Pediatr Urol 2014; 10:148-54. [PMID: 24035637 DOI: 10.1016/j.jpurol.2013.08.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Accepted: 08/01/2013] [Indexed: 10/26/2022]
Abstract
OBJECTIVE To evaluate the relationship of Wilms' tumor (WT) volume to weight, and evaluate computed tomography (CT) scan-derived final pathologic specimen weight estimation models. METHODS We retrospectively reviewed WT patients from 2003 to 2011 who had a pre-operative CT scan, final pathologic specimen weight, and tumor dimensions. A partial nephrectomy tumor cohort (n = 12) was used derive WT density. A radical nephrectomy cohort (n = 45) was used to develop a simplified estimation equation of final pathologic specimen weight, and analysis of all known estimation models was performed. RESULTS Fifty-two patients were identified. WT volume and weight were not equivalent (p = 0.0410). WT density was 1.3091 g/cm(3). WT volume and final pathologic specimen weight were not significant (p = 0.0007). Our model (p = 0.9983) and CT estimated ellipsoidal volume (p = 0.0741) were able to estimate final pathologic specimen weight in all tumors. However, CT-estimated ellipsoidal volume failed to estimate final pathologic specimen weight in specimens < 250 g (p = 0.0066). CONCLUSION Pathologic WT volume is not equivalent to final pathologic specimen weight. Final pathologic specimen weight can be estimated from a pre-operative CT scan, which suggests that it may be used to improve pre-operative surgical planning and to reduce treatment morbidity.
Collapse
Affiliation(s)
- T J Pshak
- Division of Urology, Department of Surgery, University of Colorado Anschutz Medical Campus, 12631 East 17th Ave., M/S C-319, Aurora, CO 80045, USA.
| | - D S Cho
- Division of Urology, Department of Surgery, University of Colorado Anschutz Medical Campus, 12631 East 17th Ave., M/S C-319, Aurora, CO 80045, USA
| | - K L Hayes
- Department of Radiology, Children's Hospital Colorado, 13123 East 16th Avenue, Aurora, CO 80045, USA
| | - V M Vemulakonda
- Department of Urology, Children's Hospital Colorado, 13123 East 16th Avenue Aurora, Aurora, CO 80045, USA
| |
Collapse
|
8
|
Kaur G, Smyth RL, Williamson P. Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. Trials 2012; 13:218. [PMID: 23171513 PMCID: PMC3563446 DOI: 10.1186/1745-6215-13-218] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2012] [Accepted: 10/18/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Recruitment to randomized controlled trials is known to be challenging. It is important to understand and identify predictors of good or poor accrual to a clinical trial so that appropriate strategies can be put in place to overcome these problems and facilitate successful trial completion. We have developed a survey tool to establish the recruitment experience of clinical teams regarding facilitators and barriers to recruitment in a clinical trial and describe herein the method of developing the questionnaire. METHODS A literature search was conducted to identify studies that have explored facilitators and barriers to recruitment, and a list of potential factors affecting recruitment to a clinical trial was generated. These factors were categorized in terms relating to the (i) trial, (ii) site, (iii) patient, (iv) clinical team, (v) information and consent and (vi) study team. A list was provided for responders to grade these factors as weak, intermediate or strong facilitators or barriers to recruitment. RESULTS A web-based survey questionnaire was developed. This survey was designed to establish the recruitment experience of clinical teams with regard to the perceived facilitators and barriers to recruitment, to identify strategies applied to overcome these problems, and to obtain suggestions for change in the organization of future trials. The survey tool can be used to assess the recruitment experience of clinical teams in a single/multicenter trial in any clinical setting or speciality involving adults or children either in an ongoing trial or at trial completion. The questionnaire is short, easy to administer and to complete, with an estimated completion time of 11 minutes. CONCLUSIONS We have presented a robust methodology for developing this survey tool that provides an evidence-based list of potential factors that can affect recruitment to a clinical trial. We recommend that all clinical trialists should consider using this tool with appropriate trial-specific adaptations to monitor and improve recruitment performance in an ongoing trial or conduct the survey at trial completion to gather information on facilitators and barriers to recruitment that can form the basis of interventions and strategies to improve recruitment to future clinical trials.
Collapse
Affiliation(s)
- Geetinder Kaur
- Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool, Institute of Child Health, Alder Hey Children’s Hospital, Eaton Road, Liverpool, L12 2AP, UK
- Department of Biostatistics, Faculty of Health and Life Sciences, University of Liverpool, Brownlow Street, Liverpool, L69 3GS, UK
| | - Rosalind L Smyth
- UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK
| | - Paula Williamson
- Department of Biostatistics, Faculty of Health and Life Sciences, University of Liverpool, Brownlow Street, Liverpool, L69 3GS, UK
| |
Collapse
|